DDrare: Database of Drug Development for Rare Diseases

225. 先天性腎性尿崩症
［臨床試験数：12，薬物数：45（DrugBank：17），標的遺伝子数：30，標的パスウェイ数：63］

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACETAZOLAMIDE; Acetate; Acetazolamide; Acetazolamide Sandoz 250; Adempas; Amiloride; Atorvastatin; CALCITONIN (SALMON); Calcitonin; Chlorothiazide; Confortid; DESMOPRESSIN ACETATE TRIHYDRATE; Desmopressin; Desmopressin acetate trihydrate; Desmopressine; Desmopressine nasal spray 10 mg/ml, flacon 60 doses; Esidrix; FLUCONAZOLE; Fluconazole; HYDROCHLOROTHIAZIDE; Hydrochloorthiazide; Hydrochlorothiazide; Hydrochlorothiazide/amiloride; INDOMETACIN; Indometacin; Indomethacin; Losec; Magnesium; Metformin; Miacalcic; Midamor; OMEPRAZOLE MAGNESIUM; Omeprazole; RIOCIGUAT; Riociguat; SILDENAFIL; SILDENAFIL CITRATE; SPIRONOLACTONE; SUB21605; Salmon; Sildenafil; Spirix; Spironolactone; Tolvaptan; Viagra

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-001591-30-DK (EUCTR)	06/11/2017	09/03/2017	Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil	Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil	Nephrogenic diabetes insipidus because of AVP2R-mutation MedDRA version: 20.0;Level: LLT;Classification code 10012626;Term: Diabetes nephrogenic (excludes glycosuria);System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Odense University Hospital	NULL	Not Recruiting			Female: no Male: yes	2	Phase 2	Denmark
2	EUCTR2006-003360-56-DK (EUCTR)	28/08/2009	07/07/2009	Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY	Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY	Kongenit nefrogen diabetes insipidus MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: Confortid INN or Proposed INN: INDOMETACIN Trade Name: Losec INN or Proposed INN: OMEPRAZOLE MAGNESIUM Trade Name: Viagra Other descriptive name: SILDENAFIL CITRATE Trade Name: Miacalcic Other descriptive name: CALCITONIN (SALMON) Trade Name: Spirix Other descriptive name: SPIRONOLACTONE Trade Name: Esidrix Product Name: Esidrix INN or Proposed INN: HYDROCHLOROTHIAZIDE	Dept. of Pediatrics, The Childrens Hospital, Denver	NULL	Not Recruiting			Female: no Male: yes	40		Denmark
3	NCT00478335 (ClinicalTrials.gov)	May 2007	23/5/2007	Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus	Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus	Nephrogenic Diabetes Insipidus	Drug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide /amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitonin	University of Colorado, Denver	University of Aarhus	Completed	5 Years	25 Years	Male	4	N/A	United States;Denmark

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2016-001591-30-DK
(EUCTR)

06/11/2017

09/03/2017

Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil

Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil

Nephrogenic diabetes insipidus because of AVP2R-mutation
MedDRA version: 20.0;Level: LLT;Classification code 10012626;Term: Diabetes nephrogenic (excludes glycosuria);System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Odense University Hospital

NULL

Not Recruiting

Female: no
Male: yes

Phase 2

Denmark

EUCTR2006-003360-56-DK
(EUCTR)

28/08/2009

07/07/2009

Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY

Kongenit nefrogen diabetes insipidus
MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders

Trade Name: Confortid
INN or Proposed INN: INDOMETACIN
Trade Name: Losec
INN or Proposed INN: OMEPRAZOLE MAGNESIUM
Trade Name: Viagra
Other descriptive name: SILDENAFIL CITRATE
Trade Name: Miacalcic
Other descriptive name: CALCITONIN (SALMON)
Trade Name: Spirix
Other descriptive name: SPIRONOLACTONE
Trade Name: Esidrix
Product Name: Esidrix
INN or Proposed INN: HYDROCHLOROTHIAZIDE

Dept. of Pediatrics, The Childrens Hospital, Denver

NULL

Not Recruiting

Female: no
Male: yes

Denmark

NCT00478335
(ClinicalTrials.gov)

May 2007

23/5/2007

Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

Nephrogenic Diabetes Insipidus

Drug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide /amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitonin

University of Colorado, Denver

University of Aarhus

Completed

5 Years

25 Years

Male

N/A

United States;Denmark